Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for Camrelizumab + Chemotherapy in Advanced Esophageal Cancer
NCT05174156Phase 2Unknown
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05174156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174156.